All In Biotech

Investigational drug · Phase 3

QTORIN 3.9% rapamycin anhydrous

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cutaneous Venous Malformations, Microcystic Lymphatic Malformation.

Phase 3

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

4

Any phase or sponsor naming "QTORIN 3.9% rapamycin anhydrous"

First trial start

2024

Jul 31, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "QTORIN 3.9% rapamycin anhydrous", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Cutaneous Venous Malformations
  • Microcystic Lymphatic Malformation

Largest trials

Live from ClinicalTrials.gov: studies naming "QTORIN 3.9% rapamycin anhydrous" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.